🔗 Share this article

As the US proceeds with sweeping changes to its vaccine schedules, one figure has surfaced somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who rose to prominence by casting doubt on COVID-19 vaccines during the pandemic and has concentrated on alleged deaths after COVID-19 vaccination in her brief time at the Food and Drug Administration.

Scheduled Changes to Childhood Immunization Schedule

Health officials had intended to announce radical changes to the childhood vaccination calendar in December, synchronizing the US with Denmark’s national calendar, it is understood – a substantial departure that would place the US out of step with many the global community with insufficient data for public health gain. This reveal has been pushed back until the next year.

Rather than Vinay Prasad, Dr. Høeg is set to address the audience at the event. She was just designated acting director of the FDA’s CDER, the fifth person to run the center this year.

A Shift at the Agency

This interim role could signify a closer partnership between the drug and vaccine divisions as Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it points to a greater focus upon rolling back long-standing immunizations at the FDA.

Høeg has repeatedly called for discontinuing some pediatric shot schedules in the US in order to be more in line with Denmark, a nation with nationalized medicine and a number of inhabitants approximately the population of Wisconsin’s.

So far statements, she has kept her attention on vaccination policy – typically the domain of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Concerns Over Background

Dr. Høeg has little discernible background in drug development, approval processes or leadership, which has been standard for past leaders of the CBER. She has been employed at the FDA as a top consultant to the agency head and CBER since spring.

“She doesn’t seem to have the requisite experience” for leading the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She lacks experience running a clinical trial. She lacks experience in leading a major agency. She lacks background in drug approvals.”

Previous commissioners of CBER would “understand legal statutes and the underlying principles of medication creation”, said Dr. Janet Woodcock. “Objectively, she lacks the sort of resume that prior appointees who led the center have had.”

The drug center has an immense range of responsibilities at the agency, she pointed out.

“The public just zeroes in on the new drug program, but the generic drug division approves thousands of generic medications. There is also a biosimilars division, non-prescription drug unit and other areas, and every single one have to be looked after,” she explained. “The responsibility you neglect, that is precisely what that I always told people is going to cause problems.”

Additionally, a significant administrative element to the role, which supervises more than 5,000 personnel. “It’s a massive administrative position, if you perform it correctly,” she said.

Agency Reaction and Controversial Programs

In response to inquiries about Dr. Høeg's fitness for the role and whether this appointment signifies greater collaboration among FDA leaders on vaccines, a representative responded that the “inquiries stem from incorrect presumptions”.

“Her resume is consistent with the functions of her job,” the official stated, pointing to the months Dr. Høeg spent counseling the agency head on “drug safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Høeg assumes responsibility for the commissioner’s new expedited review system, a disputed one-day medication authorization process that apparently worried her predecessors. “By what process are these therapies being selected for this fast-track system? Who takes the calls?” Howard asked. “There is a lot of confidentiality occurring at the regulatory body right now.”

Broadly speaking, he remarked, “the FDA looks to be trending towards less stringent oversight of pharmaceuticals, aside from vaccines.”

Public History on Immunizations

Concerning vaccines, Høeg has a more established, if concerning, track record, Howard have noted. She published a research paper using unverified public submissions to assess the rate of heart inflammation following Covid immunization. She advised the Florida surgeon general Dr. Joseph Ladapo, who was said to have changed statistics to indicate Covid vaccines are pose a greater threat than they are.

Among her “desired changes” for the new government included altering guidelines for recently developed shots and discontinuing “unnecessary” vaccines, she remarked following the vote on a online show. At the agency, Høeg has allegedly suggested excluding adolescent males from obtaining Covid vaccinations.

“She’s an complete true believer who commences with her preconceived notions and tailors the evidence to accommodate the science in a very misleading, fraudulent fashion,” Dr. Howard said.

Consolidating Power and a “Push for Payback”

Høeg joined fellow contrarians, {like|